Chemistry: molecular biology and microbiology – Treatment of micro-organisms or enzymes with electrical or... – Modification of viruses
Reexamination Certificate
1997-10-26
2001-09-25
Weber, Jon P. (Department: 1651)
Chemistry: molecular biology and microbiology
Treatment of micro-organisms or enzymes with electrical or...
Modification of viruses
C435S173100, C435S236000, C435S002000
Reexamination Certificate
active
06294361
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention concerns a method to inactivate viruses in biological compositions, for example, in whole blood or red blood cell concentrates, without incurring substantial disruption or inactivation of cells, for example, without adversely affecting red blood cell structure or function, by using a photoactive compound, for example, a phthalocyanine, together with light exposure and variations thereon.
2. Description of Related Art
Nature of the Concept
Substantial progress has been made in reducing the viral infectivity of whole blood and its components through improved donor selection and donor blood screening procedures. Despite this progress, there is a continued risk of transmission of viruses including hepatitis viruses and human immunodeficiency viruses (HIV) by whole blood and blood products.
The risk of transmission of certain viruses (e.g., hapatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV)) has been considerably reduced and possibly eliminated in coagulation factor concentrates through the application of virucidal procedures during the course of manufacture (Prince, A. M., Horowitz, B., Horowitz, M. S., Zang, E., “The Development of Virus-Free Labile Blood Derivatives—A Review”,
Eur. J. Epidemiol
., 1987; 3:103-118 and Mannucci, P. M., Colombo, M., “Virucidal Treatment of Clotting Factor Concentrates”,
The Lancet
, 1988;782-785). However, when treating coagulation factor concentrates, some viruses (e.g., parvovirus) may remain infectious. In addition, the development of virucidal processes applicable to cell components, i.e., blood cell fractions such as red blood cells or platelets, has been slow, both because cells are more fragile than proteins, and cells serve to harbor and protect virus against inactivation. Nonetheless, if virus transmission by whole blood or blood components is to be eliminated, effective virus removal or potent virucidal methods applicable to blood cells will be required. Since both red blood cells or platelets are non-replicating, approaches directed toward nucleic acid modification might offer the required specificity.
It is important to recognize in assessing virucidal procedures for cell-containing solutions that virus will be present in multiple forms: virus free of the cell; formed virus associated with the cell; functional, but unpackaged viral nucleic acid within the cell; and viral nucleic acid integrated into the cell genome. Each form should be considered infectious and capable of causing viral disease in vivo. Virucidal methods which inactivate virus in one form, e.g., cell-free virus, may not inactivate virus in other forms, e.g., cell-associated forms. Additionally, the presence of cells is known to inhibit the action of both physical and chemical approaches to virus inactivation. Cells compete for added virucidal reagents and absorb radiation which otherwise would be virucidal. Thus, for example, while ultraviolet irradiation is highly virucidal in salt solutions or in dilute protein solution, the degree of virucidal activity is incomplete when treating cell-containing solutions. Furthermore, in this context, it is not sufficient to inactivate virus alone; rather, it is necessary to do so with sufficient vigor that viral infectivity is eliminated without deleterious effects to the valuable cell components, e.g., red blood cells.
Most virucidal procedures which have been developed, e.g., pasteurization or solvent/detergent treatment, cannot be applied to blood cell preparations without damaging the cells and rendering them unfit for transfusion.
Heretofore, it has not been possible to prepare virus sterilized forms of whole blood or red cell concentrates or platelet concentrates where at least 10
4
infectious units (ID
50
) and preferably ≧10
6
ID
50
of both intracellular and extracellular virus were inactivated without adversely affecting the cells and/or without using highly toxic agents.
Phthalocyanines
While there has been growing interest in the use of phthalocyanines for the treatment of cancerous cells (Rosenthal, I. and Ben Hur, E., “Phthalocyanines in Photobiology”, Lezhoff C. C. and Lever A. B. P. eds.,
Phthalocyanines
, VCH Publishers, Inc., New York, N.Y., 1989, 393-425), phthalocyanines are generally thought of as being hemolytic, making applicants' results herein all the more surprising. For example, Ben-Hur and Rosenthal (“Photohemolysis of Human Erthrocytes Induced by Aluminum Phthalocyanine Tetrasulfonate”,
Cancer Lett
., 30: 321-327, 1986) studied the photohemolysis of human red blood cells induced by aluminum phthalocyanine tetrasulfonate. Substantial (20-100%) hemolysis was induced by treatment with 2.5 to 10 &mgr;M AlPCS
4
at all light fluences≧40 KJ/m
2
(≧4 J/cm
2
). Ben-Hur and Rosenthal did not address the problem of virus kill. Similarly, Sonoda, Krishna and Riesz (“The Role of Singlet Oxygen in the Photohemolysis of Red Blood Cells Sensitized by Phthalocyanine”,
Photochem. Photobiol
., 46: 625-631, 1987) studied the photohemolysis induced by each of several phthalocyanine derivatives. Aluminum and zinc phthalocyanines were each hemolytic, while free (no metal) phthalocyanine or those with iron, copper or cobalt as the central metal cation were not. Virus kill was not studied.
Singer et al (C. R. J. Singer, T. Azim and Q. Sattentau, “Preliminary Evaluation of Phthalocyanine Photosensitization For Inactivation Of Viral Pathogens in Blood Products”, [abstract]
British J. Hematology
, Mar. 23-25, 1988:Abs. 31), in what is believed to be the only study on virus kill performed with phthalocyanines, demonstrated that an unstated quantity of both Epstein Barr virus and of HIV added to plasma was inactivated on treatment with 5 and 25 &mgr;g/mL of sulfonated aluminum phthalocyanine and 2 mW/cm
2
for 30 minutes (3.6 J/cm
2
). Factor VIII recovery was only 50%. Singer et al reported no actual work on cells or cell-associated virus, though they state that application to red cells is being evaluated. Given the relatively poor recovery (50%) of factor VIII reported by Singer, the greater fragility of cells than proteins, and the previous experience on the photohemolysis of red cells to treatment with phthalocyanine, the results herein are all the more surprising.
Other Lipophilic Dyes in the Treatment of Whole Blood or Red Blood Cell Concentrates
Cole et al (Cole, M., Stromberg, R., Friedman, L., Benade, L., Shumaker, J., “Photochemical Inactivation of Virus in Red Cells”,
Transfusion
, 29, Supp:42s Abs., 1989) explored the use of merocyanine 540 in the treatment of packed red blood cells diluted to a hematocrit of 15%. When plasma was removed such that its concentration was 2.6%, a 6 log reduction of vesicular stomatitis virus was achieved. However, only a 1 log reduction in VSV was achieved in samples containing 15% plasma. The authors concluded that “although plasma is required to protect the red blood cells from damage, viral kill is also significantly reduced”. This conclusion is supported by the observation that the presence of 5% albumin inhibited virus kill in suspension of washed platelets (Prodouz, K. N., “Effect of Merocyanine 540 on Platelet Function and Reduction of its Antiviral Activity by Albumin”,
Transfusion
, 29, Supp:42s Abs., 1989), and that though 6 logs of model viruses in buffer could be inactivated by merocyanine 540, only 1-3 logs of virus could be inactivated in the presence of 12-25% plasma (Moroff, G., Benade, L. E., Dabay, M., George, V. M., Shumaker, J. and Dodd, R. Y., “Use of Photochemical Procedures to Inactivate Viruses in Platelet Suspensions”,
Transfusion
, 29, Supp:S15 Abs., 1989). Furthermore, the authors stated that the procedure “adversely affected platelet properties”.
Matthews, J. T., Newman, J. T., Sogandares-Bernal, F., et al, “Photodynamic Therapy of Viral Contaminants with Potential For Blood Banking Applications”,
Transfusion
, 1988;28:81-83 studied treatment of whole blood with hematoporphyrin derivatives and light. They reported the
Geacintov Nicholas E.
Horowitz Bernard
Nunno Henrietta
Rywkin Shanti B.
Valinsky Jay E.
Amster Rothstein & Ebenstein
New York Blood Center Inc.
Weber Jon P.
LandOfFree
Processes for photoreactive inactivation of a virus in blood... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Processes for photoreactive inactivation of a virus in blood..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Processes for photoreactive inactivation of a virus in blood... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2472203